





NRTEMIS

AcceleRating
the Translation
of virtual twins
towards a
pErsonalized
Management of
fatty liver patients





ARTEMIs is destined to set bridges among key stakeholders involved in the fight against fatty liver diseases. In the dawning of the Personalized Medicine Era, ARTEMIs aims at gathering clinicians, modelers, patients, and regulators towards the development of a comprehensive therapeutic decision-aid tool. To do so, ARTEMIs is grounded upon three building blocks: a multimodal and regulatory-grade cohort; liver-heart virtual twins and a user-friendly Smart Dashboard.

We expect to achieve considerable societal impact, by offering clinicians and patients an interactive visualization tool wherein real-world data, as well as risk stratification and early diagnosis predictions are made easy. This is an ambitious project involving 9 countries, 21 partners and a cohort of 7500 patients but ambition is a fundamental ingredient when taking the challenge to improve MAFLD patients' healthcare journey!

Aligning Expertise:

ARTEMIs Team's Shared Vision























Understanding MAFLD Progression: A Gateway to Effective Management

Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD) now dominates chronic liver disease (CLD) in Europe, surpassing viral hepatitis and alcohol-related causes, with a prevalence exceeding 25%. This rise is linked to escalating risk factors from unhealthy lifestyles. MAFLD's diverse clinical trajectory, including steatosis, NASH, cirrhosis and hepatocellular carcinoma, stems from varied underlying mechanisms. In particular, the inflammatory facet - non-alcoholic steatohepatitis (NASH) - heightens cardiovascular disease (CVD) risk, a leading cause of death in MAFLD patients. Understanding MAFLD progression and the liver-heart axis is crucial for effective management. This consortium will develop liver and heart computational models and virtual twins, offering insights into heart-liver functions across different stages of the disease.



Empowering Precision Healthcare with ARTEMIS

ARTEMIs aims to co-design and develop a proof-of-concept (POC) of a Smart Dashboard—a cuttingedge clinical decision support system - offering an overview of patient multimodal data and therapeutic decision-aid, thanks to the integrated virtual twin models. From early diagnosis to predicting disease evolution, assessing cardiovascular outcomes, and guiding specific treatments or interventions, the Smart Dashboard provides dynamic, multilevel representations of tissues and organs. This approach empowers clinicians to implement personalized and responsive care strategies, marking a significant leap forward in MAFLD patient management.

The project will focus on 4 clinical cases, each one addressing a stage of the MAFLD progression:



Fibrosis progression in MAFLD patients




Fibrosis-associated heart failure patients



Cardiovascular complications after TIPS placement (Portal Hypertension)



Prediction of cardiac complications due to HCC treatments





Showcasing 5 Transformative Deliverables from a Suite of Project Outcomes

ARTEMIs envisages filling in the gaps of virtual twins' state-of-the-art and, at to offer clinicians a friendly-user, therapeutic decision-aid device to improve MAFLD healthcare pathway. Here are some transformative deliverables that ARTEMIS will bring about:

- Integrated model (virtual twin) demonstrator per use case
- POC Feasibility Study design for each use case
- Clinical Decision Support System (CDSS) final version
- **♥ POC Feasibility Study results** for each use case
- Societal impact assessment









Scaling the ARTEMIS Model for Transformative Impact

The ARTEMIS model is designed for scalable deployment with the goal of extending its impact to enhance healthcare across various organs and therapeutic interventions, fostering improved decision-making. As radiogenomics unveils mechanistic pathways in cancer cells, ARTEMIS' Clinical Decision Support System (CDSS) will evolve to offer an interactive, user-friendly presentation of patients' multimodal data.

We envision furthering integration and development of state-of-the-art computational models within new European Consortia in the near future.

30 MONTH

36 MONTH

42 MONTH

48 MONTH

MS4
VT submodels
developed

MS5
CDSS version
with integrated
liver-heart VT

MS6
Final evaluation ready to start

Fully functional CDSS, steps towards regulatory approval & commercial exploitation defined

Fostering Collaboration through Thoughtful Governance



Vlad Ratziu

Professor of Hepatology Expert NASH/NAFLD

ROI F

ARTEMIs Clinical Coordinator

INSTITUTION

Institute of Cardiometabolism and Nutrition (ICAN)



Raul Herance

Professor of Hepatology Expert NASH/NAFLD

ROI F

Clinical Coordinator

INSTITUTION

Institute of Cardiometabolism and Nutrition (ICAN)



Raluca **Pais**

Gastroenterologist and hepatologist

ROI F

Clinical Coordinator of Clinical Case #1: Progression of fibrosis on MAFLD patients

INSTITUTION

Institute of Cardiometabolism and Nutrition (ICAN)



Norbert Frey

Professor, Medical Director – Cardiology Dept.

Clinical Coordinator of Clinical Case #2: Fibrosis-associated heart failure patients

INSTITUTION

Universitats Klinikum Heidelberg (UKHD)



Florian Leuschner

Prof. Dr. Immunocardiology

Clinical Coordinator of Clinical Case #2 (Fibrosis-associated heart failure patients)

INSTITUTION

Universitats Klinikum Heidelberg (UKHD) Nutrition (ICAN)



Cristina **Ripoll**

Associate Professor, Internal Medicine IV (Gastroenterology, Hepatology and Infectious diseases)

ROLE

Clinical Coordinator of Clinical Case #3: Cardiovascular events post TIPS placement (Portal Hypertension)

INSTITUTION

Universität's Klinikum Jena (JUH)



Giuliana **Amaddeo**

Hepatologist and Senior Lecturer

Clinical Coordinator of Clinical Case #4: Prediction of cardiac complications due to HCC treatments

INSTITUTION

Assistance Publique-Hôpitaux de Paris (AP-HP)



Irène Vignon-Clementel

JOB TITLE Research Director

SCIENTIFIC COMMITTEE

ARTEMIs Scientific Coordinator and Scientific Coordinator of Clinical Case #3: Cardiovascular events post TIPS placement (Portal Hypertension)

INSTITUTION

Institut national de recherche en sciences et technologies du numérique (INRIA)



Dirk Drasdo

JOB TITLE

Research Director

Scientific Coordinator of Clinical Case #1: Progression of fibrosis on MAFLD patients

INSTITUTION

Institut national de recherche en sciences et technologies du numérique (INRIA)



Ursula Klingmüller

Head of Computational Systems Biology Group

ROLE

Scientific Coordinator of Clinical Case #2: Fibrosis-associated heart failure patients

INSTITUTION

Deutsches Krebsforschungszentrum (DKFZ)



Stefan Hoehme

JOB TITLE

Project leader

Scientific Coordinator of Clinical Case #4: Prediction of cardiac complications due to HCC treatments

INSTITUTION

Universität Leipzig



Mario Aznar

Founder and Managing Partner

Technical Coordinator

INSTITUTION

Matical



Cristina d'Almeida

Project Coordinator

Scientific Director

INSTITUTION

Medexprim



Laure Saint-Aubert

JOB TITLE

Project Director ROLE

Project Director

INSTITUTION Medexprim



Laura Muñoz

JOB TITLE Scientific Director


ROLE

Technical Coordinator

INSTITUTION

Matical





Contact mail Page linkedin

Website to come